Literature DB >> 17717066

Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources.

Susan M Graham1, J Keith Vass, Tessa L Holyoake, Gerard J Graham.   

Abstract

Quiescent and dividing hemopoietic stem cells (HSC) display marked differences in their ability to move between the peripheral circulation and the bone marrow. Specifically, long-term engraftment potential predominantly resides in the quiescent HSC subfraction, and G-CSF mobilization results in the preferential accumulation of quiescent HSC in the periphery. In contrast, stem cells from chronic myeloid leukemia (CML) patients display a constitutive presence in the circulation. To understand the molecular basis for this, we have used microarray technology to analyze the transcriptional differences between dividing and quiescent, normal, and CML-derived CD34+ cells. Our data show a remarkable transcriptional similarity between normal and CML dividing cells, suggesting that the effects of BCR-ABL on the CD34+ cell transcriptome are more limited than previously thought. In addition, we show that quiescent CML cells are more similar to their dividing counterparts than quiescent normal cells are to theirs. We also show these transcriptional differences to be reflected in the altered proliferative activity of normal and CML CD34+ cells. Of the most interest is that the major class of genes that is more abundant in the quiescent cells compared with the dividing cells encodes members of the chemokine family. We propose a role for chemokines expressed by quiescent HSC in the orchestration of CD34+ cell mobilization. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17717066     DOI: 10.1634/stemcells.2007-0250

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  40 in total

1.  Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.

Authors:  Hein Than; Anthony D Pomicter; Dongqing Yan; Larry P Beaver; Anna M Eiring; William L Heaton; Anna Senina; Phillip M Clair; Sharon Shacham; Clinton C Mason; Thomas O' Hare; Michael W Deininger
Journal:  Leukemia       Date:  2020-01-24       Impact factor: 11.528

2.  Paired Related Homeobox Protein 1 Regulates Quiescence in Human Oligodendrocyte Progenitors.

Authors:  Jing Wang; Darpan Saraswat; Anjali K Sinha; Jessie Polanco; Karen Dietz; Melanie A O'Bara; Suyog U Pol; Hani J Shayya; Fraser J Sim
Journal:  Cell Rep       Date:  2018-12-18       Impact factor: 9.423

3.  Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Authors:  Kristen Meldi; Tingting Qin; Francesca Buchi; Nathalie Droin; Jason Sotzen; Jean-Baptiste Micol; Dorothée Selimoglu-Buet; Erico Masala; Bernardino Allione; Daniela Gioia; Antonella Poloni; Monia Lunghi; Eric Solary; Omar Abdel-Wahab; Valeria Santini; Maria E Figueroa
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

Review 4.  Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.

Authors:  Y Chen; C Peng; C Sullivan; D Li; S Li
Journal:  Leukemia       Date:  2010-06-24       Impact factor: 11.528

5.  Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1.

Authors:  Fengyin Li; Bing He; Xiaoke Ma; Shuyang Yu; Rupali R Bhave; Steven R Lentz; Kai Tan; Monica L Guzman; Chen Zhao; Hai-Hui Xue
Journal:  Cell Stem Cell       Date:  2017-08-30       Impact factor: 24.633

6.  Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.

Authors:  Vladan P Čokić; Slavko Mojsilović; Aleksandra Jauković; Nada Kraguljac-Kurtović; Sonja Mojsilović; Dijana Šefer; Olivera Mitrović Ajtić; Violeta Milošević; Andrija Bogdanović; Dragoslava Đikić; Pavle Milenković; Raj K Puri
Journal:  Blood Cells Mol Dis       Date:  2015-08-07       Impact factor: 3.039

7.  hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.

Authors:  Francesca Pellicano; Laura Park; Lisa E M Hopcroft; Mansi M Shah; Lorna Jackson; Mary T Scott; Cassie J Clarke; Amy Sinclair; Sheela A Abraham; Alan Hair; G Vignir Helgason; Mark Aspinall-O'Dea; Ravi Bhatia; Gustavo Leone; Kamil R Kranc; Anthony D Whetton; Tessa L Holyoake
Journal:  Blood       Date:  2018-02-05       Impact factor: 22.113

8.  CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia.

Authors:  P M Korthuis; G Berger; B Bakker; M Rozenveld-Geugien; J Jaques; G de Haan; J J Schuringa; E Vellenga; H Schepers
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

9.  HOXC4 homeoprotein efficiently expands human hematopoietic stem cells and triggers similar molecular alterations as HOXB4.

Authors:  Céline Auvray; Andrée Delahaye; Françoise Pflumio; Rima Haddad; Sophie Amsellem; Ayda Miri-Nezhad; Loïc Broix; Azzedine Yacia; Frédérique Bulle; Serge Fichelson; Isabelle Vigon
Journal:  Haematologica       Date:  2012-02       Impact factor: 9.941

10.  Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.

Authors:  Yaoyu Chen; Yiguo Hu; Haojian Zhang; Cong Peng; Shaoguang Li
Journal:  Nat Genet       Date:  2009-06-07       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.